A reconciliation of the beginning and ending amount of unrests for the years ended December 31, 2023, 2022 and 2021 is as follows:

| (in thousands)                                         |    |         |
|--------------------------------------------------------|----|---------|
| Unrecognized tax benefits balance at December 31, 2020 | ക  | 1,340   |
| Gross decreases for tax positions in 2021              |    | 8.771   |
| Unrecognized tax benefits balance at December 31, 2021 |    | 10.111  |
| Gross increase for rate change in 2022                 |    | (8,753) |
| Unrecognized tax benefits balance at December 31, 2022 |    | 1.358   |
| Gross decrease for tax positions in 2023               |    | 18)     |
| Unrecognized tax benefits balance at December 31, 2023 | ಕಾ | 1,340   |

The Company has \$1.3 million of unrecognized tax benefits as of December 31, 2023 that, if recognized, would impact the effective tax rate. The Company did not acrue for any interest or peraltied to unrecognized tax benefits as of December 31, 2023 and 2022 as compared to an acrual of \$3.2 million for the year ended December 31, 2021. The Company does not anticipate significant changes to our unrecognized tax benefits within the next twelve months.

## Concentration 15.

On December 14. 2022. the Company received a modification to the Company's current of Health and Human Services ("HS") and the Assistant Secretary for Presared Resorse ("ASPR") adreement that expired on February Federal Acquisition Regulation ("FAR") 52.217-8, which allows the government to extend the term of this current agreement by up to six months.

Additionally. on December 14. 2022. the Company entered into a new HHS / ASPR acreement") for breventive maintenance services ("PMS"). management and sowered air purfiving resoirator ("PAPP") systems. The Anreement's performance beriod commenced on Audust 28. 2023 and is anticibated to have a beriod of four years and six months, consisting of a base period of twelve months, three one-year option periods and an additional six-month option period.

Approximately 10.4% and 10.5% of total Company revenue was attributable to various contracts with the HHS / ASPR for the years ending December 31, 2023 and 2022, respectively.

## 16. Earnings (Loss) Per Share

The following is a reconciliation of the basic and diluted number of shares used in computing earnings (loss) per share:

|                                                                                                  |      | Year Ended December 31. |    |             |    |             |  |
|--------------------------------------------------------------------------------------------------|------|-------------------------|----|-------------|----|-------------|--|
|                                                                                                  |      | 2023                    |    | 2022        |    | 2021        |  |
| Basic weighted average shares outstanding                                                        |      | 134.647.238             |    | 132.602.747 |    | 120,877,480 |  |
| Net effect of dilutive stock awards based upon the treasury stock method                         |      |                         |    | 5,778,548   |    | 7,619,740   |  |
| Dilutive weighted average shares outstanding                                                     |      | 134,647,238             |    | 138,381,295 |    | 128,497,220 |  |
|                                                                                                  |      |                         |    |             |    |             |  |
| Basic earnings (loss) per share                                                                  | ಲ್ಲಾ | (0.14)                  | રે | 0.23        | ಕೆ | 0.20        |  |
| Diluted earnings (loss) per share                                                                | લ્ક  | (0.14)                  | ಕ  | 0.22        | ട് | 0.19        |  |
|                                                                                                  |      |                         |    |             |    |             |  |
| Anti-dilutive share-based awards excluded from the calculation of dilutive<br>earnings ner share |      | 8 557 396               |    | 9 203       |    |             |  |

For the year ended December 31, 2023, dilutive weighted in basic weighted-average shares outstanding due to the Company's net loss position as the includive weighted-average shares outstanding would be articlilitive.